
We presented the first clinical data on SOT201, our PD-1 targeting IL-15 immunocytokine, at #SITC26 recently – news which got highlighted in this article from @UTMDAnderson. Initial data from the Phase 1 VICTORIA-01 trial show early evidence of durable antitumor activity. Says @AnaingMD, professor of Investigational Cancer Therapeutics at MD Anderson, who presented the poster: “These early results are encouraging, particularly because many of these patients had already received several treatments and had limited available options.” See below for more. @sitcancer
At #SITC26, experts presented research that's exploring new approaches to treating advanced cancers, including solid tumors, brain cancer and melanoma. These insights may improve the effectiveness of immunotherapies and expand treatment options. @sitcancer #EndCancer spr.ly/6016BHhQe6












